Search results
5 days ago · Abbott Laboratories (NYSE:ABT) is a global healthcare company that specializes in a wide range of related services and products. The company benefits from the defensive nature of its industry ...
Jul 2, 2024 · Debt Management: Abbott Laboratories's debt-to-equity ratio is below the industry average at 0.38, reflecting a lower dependency on debt financing and a more conservative financial approach.
6 days ago · Abbott Laboratories last issued its quarterly earnings results on April 17th, 2024. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion for the quarter, compared to analysts' expectations of $9.88 billion.
1 day ago · Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The company had revenue of $9.96 billion during the quarter, compared to analyst estimates of $9.88 billion.
2 days ago · July 7, 2024. StoneX Group Inc. bought a new stake in shares of Abbott Laboratories ( NYSE:ABT - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,371 shares of the healthcare product maker's stock, valued at approximately $1,179,000.
Jun 28, 2024 · Abbott Laboratories also offers blood glucose monitoring meters, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products.
Jun 14, 2024 · Abbott Laboratories has a payout ratio of 42.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Abbott Laboratories to earn $5.12 per share next year, which means the company should continue to be able to cover its $2.20 annual dividend with an expected future payout ratio of 43.0%.
